The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure: the BEAT-HF trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure : the BEAT-HF trial. / Bundgaard, Henning; Axelsson, Anna; Hartvig Thomsen, Jakob; Sørgaard, Mathias; Kofoed, Klaus F; Hasselbalch, Rasmus; Fry, Natasha A S; Valeur, Nana; Boesgaard, Søren; Gustafsson, Finn; Køber, Lars; Iversen, Kasper; Rasmussen, Helge H.
I: European Journal of Heart Failure, Bind 19, Nr. 4, 04.2017, s. 566-575.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - The first-in-man randomized trial of a beta3 adrenoceptor agonist in chronic heart failure
T2 - the BEAT-HF trial
AU - Bundgaard, Henning
AU - Axelsson, Anna
AU - Hartvig Thomsen, Jakob
AU - Sørgaard, Mathias
AU - Kofoed, Klaus F
AU - Hasselbalch, Rasmus
AU - Fry, Natasha A S
AU - Valeur, Nana
AU - Boesgaard, Søren
AU - Gustafsson, Finn
AU - Køber, Lars
AU - Iversen, Kasper
AU - Rasmussen, Helge H
N1 - © 2016 The Authors. European Journal of Heart Failure © 2016 European Society of Cardiology.
PY - 2017/4
Y1 - 2017/4
N2 - AIMS: The third isotype of beta adrenergic receptors (β3 ARs) has distinctly different effects on cardiomyocytes compared with β1 and β2 ARs. Stimulation of β3 ARs may reduce cardiomyocyte Na+overload and reduce oxidative stress in heart failure (HF). We examined if treatment with the β3 AR agonist mirabegron increases LVEF in patients with HF.METHODS AND RESULTS: In a double-blind trial we randomly assigned 70 patients with NYHA class II-III HF and LVEF <40% at screening-echocardiography to receive mirabegron or placebo for 6 months as add-on to optimized standard therapy. The primary endpoint was an increase in LVEF after 6 months as measured by computed tomography (CT). Changes in LVEF after 6 months between treatment groups were not significantly different (0.4%, -3.5 to 3.8%, P = 0.82). In an exploratory analysis, based on an expectation that the pathophysiological substrate targeted with treatment is dependent on the baseline LVEF, patients with LVEF <40% by CT given mirabegron had a significant increase in LVEF while no increase was seen in patients given placebo. The changes were significantly different between groups (5.5%, 0.6-10.4%, P < 0.03). Additionally, there was interaction between baseline LVEF and change in LVEF in the entire group of patients treated with mirabegron (R2 = 0.40, β = -0.63, P < 0.001), but not in the placebo group (R2 = 0.00, β = -0.01, P = 0.95). Treatment was generally well tolerated. Three patients in each group had fatal or life-threatening events.CONCLUSIONS: The primary endpoint was not reached. Exploratory analysis indicated that β3 AR stimulation by mirabegron increased LVEF in patients with severe HF. Treatment appeared safe. Additional studies in severe HF are needed.TRIAL REGISTRATION: NCT01876433.
AB - AIMS: The third isotype of beta adrenergic receptors (β3 ARs) has distinctly different effects on cardiomyocytes compared with β1 and β2 ARs. Stimulation of β3 ARs may reduce cardiomyocyte Na+overload and reduce oxidative stress in heart failure (HF). We examined if treatment with the β3 AR agonist mirabegron increases LVEF in patients with HF.METHODS AND RESULTS: In a double-blind trial we randomly assigned 70 patients with NYHA class II-III HF and LVEF <40% at screening-echocardiography to receive mirabegron or placebo for 6 months as add-on to optimized standard therapy. The primary endpoint was an increase in LVEF after 6 months as measured by computed tomography (CT). Changes in LVEF after 6 months between treatment groups were not significantly different (0.4%, -3.5 to 3.8%, P = 0.82). In an exploratory analysis, based on an expectation that the pathophysiological substrate targeted with treatment is dependent on the baseline LVEF, patients with LVEF <40% by CT given mirabegron had a significant increase in LVEF while no increase was seen in patients given placebo. The changes were significantly different between groups (5.5%, 0.6-10.4%, P < 0.03). Additionally, there was interaction between baseline LVEF and change in LVEF in the entire group of patients treated with mirabegron (R2 = 0.40, β = -0.63, P < 0.001), but not in the placebo group (R2 = 0.00, β = -0.01, P = 0.95). Treatment was generally well tolerated. Three patients in each group had fatal or life-threatening events.CONCLUSIONS: The primary endpoint was not reached. Exploratory analysis indicated that β3 AR stimulation by mirabegron increased LVEF in patients with severe HF. Treatment appeared safe. Additional studies in severe HF are needed.TRIAL REGISTRATION: NCT01876433.
KW - Acetanilides/therapeutic use
KW - Adrenergic beta-3 Receptor Agonists/therapeutic use
KW - Adult
KW - Aged
KW - Double-Blind Method
KW - Female
KW - Heart Failure/diagnostic imaging
KW - Humans
KW - Male
KW - Middle Aged
KW - Stroke Volume
KW - Thiazoles/therapeutic use
KW - Tomography, X-Ray Computed
U2 - 10.1002/ejhf.714
DO - 10.1002/ejhf.714
M3 - Journal article
C2 - 27990717
VL - 19
SP - 566
EP - 575
JO - European Journal of Heart Failure
JF - European Journal of Heart Failure
SN - 1567-4215
IS - 4
ER -
ID: 193896608